Sinntaxis was founded 2017 by scientists at Lund University and LU Holding AB. The company is managed by a team with vast experience in neuroscience/stroke research and pharmaceutical drug development and business development.
Sinntaxis has an established discovery platform for preclinical studies of stroke recovery, and has filed IP on the use of negative allosteric modulators of the metabotropic glutamate receptor 5 for the treatment of stroke recovery.
Sinntaxis has established a global network of Key Opinion Leaders ranging from experimental research to clinical trial in stroke recovery.
17 million individuals are afflicted by stroke every year
5 million are in need of daily care due to life-long sensory, motor and cognitive disabilities
Research & development
Stroke is treated within hours after onset with removal of the obstructive clot in the brain vessels, but less than 10% of the stroke patients receive this therapy. There are no approved drugs that support rehabilitation and that enhance recovery of brain function after stroke. All stroke patients could be eligible for this treatment.
The Sinntaxis Approach
The graph shows improved restoration of brain function using therapy developed by Sinntaxis.
Employing mGlur5 inhibitors to restore brain function after stroke:
- mGluR5 activation is detrimental for recovery of lost brain functions after stroke
- mGluR5 inhibitors enhance recovery of lost brain functions
- mGluR5 inhibitors beneficially remodel brain connectivity by synaptic remodelling
- Start of treatment an extended period after brain insult is still effective
- Combined treatment of mGluR5 inhibitors with training synergistically enhances recovery
Tomas Eriksson appointed CEO of Sinntaxis AB
Tomas Eriksson is new CEO of the pharmaceutical company Sinntaxis from April 1, as current CEO Michael Oredsson will move from Sweden. Tomas Eriksson most recently comes from the CEO post at the listed company A1M Pharma. Sinntaxis is a portfolio company at LU Holding and a member of SmiLe Incubator in Lund
Michael Oredsson appointed CEO of Sinntaxis AB
The former CEO of public companies BioInvent och Probi, Michael Oredsson, has been appointed CEO of Sinntaxis AB, a young biotech company in Lund developing a new drug for stroke recovery. Lars Grundemar, with extensive international experience from the pharma industry, has been appointed Chairman of the Board. The company is based on research conducted by Tadeusz Wieloch and his group at Lund university.